Drug Profile
DRL 17822
Alternative Names: CZ0L3; DRL-17822Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Dr Reddys Laboratories
- Developer Centre for Human Drug Research; Dr Reddys Laboratories
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hyperlipoproteinaemia type II
- No development reported Atherosclerosis; Dyslipidaemias
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in Netherlands (PO, Capsule)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Atherosclerosis(In volunteers) in India (PO, Capsule)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in India (PO, Capsule)